We invest in a broad range of public companies across the global life sciences market.

Pivotal’s public equity team invests in publicly listed companies with innovative therapeutics, devices, or biomedical tools that are underappreciated by the market. We invest globally and primarily in the small- to mid-cap space. We leverage deep fundamental research and rigorous financial analysis to help select potentially undervalued companies, with a focus on opportunities with specific catalysts, in order to achieve attractive long-term risk adjusted returns.